Sugi Predict

Sugi Predict / Compounds / SCHEMBL310405

SCHEMBL310405

SCHEMBL310405

CC(C)(C)OC(=O)N1CCC(CCO)CC1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.54
▸ KDM4E B2RXH2 2/20 0.52
▸ PKM P14618 1/20 0.52
▸ NR1H2 P55055 1/20 0.51
▸ RECQL P46063 1/20 0.51
▸ EPHX1 P07099 1/20 0.51
▸ GPR119 Q8TDV5 6/20 0.51
▸ FAAH O00519 1/20 0.50
▸ USP2 O75604 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ MAPT P10636 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ PTPN2 P17706 1/20 0.47
▸ PTPN1 P18031 1/20 0.47
▸ PTPN6 P29350 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31662254 1.00 HPGD (0.54) HPGDKDM4EPKMNR1H2RECQL
SCHEMBL5387542 0.94 HPGD (0.56) HPGDKDM4EPKMNR1H2RECQL
SCHEMBL31662078 0.92 NR1H2 (0.51) HPGDKDM4EPKMNR1H2RECQL
SCHEMBL6398279 0.92 NR1H2 (0.51) HPGDKDM4EPKMNR1H2RECQL
SCHEMBL344474 0.92 NR1H2 (0.51) HPGDKDM4EPKMNR1H2RECQL
SCHEMBL364778 0.92 NR1H2 (0.51) HPGDKDM4EPKMNR1H2RECQL
SCHEMBL22181207 0.91 HPGD (0.47) HPGDKDM4EPKMNR1H2RECQL
SCHEMBL560636 0.90 GPR119 (0.55) HPGDKDM4EPKMNR1H2RECQL
SCHEMBL1576008 0.89 GPR119 (0.56) HPGDKDM4EPKMNR1H2RECQL
SCHEMBL22633428 0.88 HPGD (0.53) HPGDKDM4EPKMNR1H2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101081846-A Quinazoline derivative and preparation method and usage thereof WUWEI MEDICINE TECHNOLOGY SHAN (CN) 2007-12-05 — — CN claimed
US-20040044044-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-03-04 — — US claimed
US-20040039029-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-02-26 — — US claimed
US-6645990-B2 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases AMGEN INC. 2003-11-11 — — US claimed
EP-1309589-A2 UREA COMPOUNDS AND METHODS OF USES Amgen Inc. (US) 2003-05-14 — — EP claimed
US-20020193405-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2002-12-19 — — US claimed
US-20020173507-A1 Urea compounds and methods of uses AMGEN INC. 2002-11-21 — — US claimed
WO-2002014311-A2 UREA COMPOUNDS AND METHODS OF USES AMGEN INC. (US) 2002-02-21 — — WO claimed
JP-5017498-A — — None — — JP disclosed
US-12637480-B2 Heterocyclic compounds as sting modulators BEONE MEDICINES I GMBH (CH) 2026-05-26 — — US disclosed
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
EP-4166557-B1 INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES NOVARTIS AG (CH) 2026-05-06 — — EP disclosed
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-02 — — US disclosed
EP-0479481-A2 Fibrinogen receptor antagonists MERCK & CO. INC. (US) 1992-04-08 — — EP disclosed
CN-1060096-A FIBRINOGEN RECEPTOR ANLAGONISTS MERCK & CO INC (US) 1992-04-08 — — CN disclosed
EP-0478362-A2 Fibrinogen receptor antagonists MERCK & CO. INC. (US) 1992-04-01 — — EP disclosed
EP-0094766-B1 QUINAZOLINE CARDIAC STIMULANTS Pfizer Limited (GB) 1986-12-30 — — EP disclosed
US-4489075-A Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants PFIZER INC. (US) 1984-12-18 — — US disclosed
EP-0094766-A2 Quinazoline cardiac stimulants Pfizer Limited (GB) 1983-11-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 HPGD 3257/4885KDM4E 810/4885PKM 1429/4885
US-20020193405-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX HPGD 672/4885KDM4E 2714/4885PKM 580/4885
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 HPGD 2098/4885KDM4E 1888/4885PKM 3718/4885
US-20020173507-A1 Urea compounds and methods of uses SLC14A1, UMPS, BAX HPGD 329/4885KDM4E 1709/4885PKM 1064/4885
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF BCL2L2, BCL2A1, BCL2L1 HPGD 1899/4885KDM4E 3398/4885PKM 4390/4885
US-20040039029-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX HPGD 672/4885KDM4E 2714/4885PKM 580/4885
US-12637480-B2 Heterocyclic compounds as sting modulators STING1, IFNAR1, IRF3 HPGD 3755/4885KDM4E 3830/4885PKM 4593/4885
US-20040044044-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX HPGD 672/4885KDM4E 2714/4885PKM 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.